Covaxin, India’s first COVID-19 vaccine, is effective against new variant, says Bharat Biotech

India’s first indigenous COVID-19 vaccine, Covaxin, currently undergoing Phase 3 trials, can be effective against the new variant of coronavirus.

By: Jahnavi Sarma | | Updated: December 31, 2020 8:06 am

The new variant of COVID-19, which was detected in the UK, is quickly spreading across the world. India too has detected the strain in samples taken from people returning from the UK. This new strain of coronavirus is said to be more transmittable and the government and experts are leaving no stones unturned to prevent its transmission in the country. The main worry now in most people’s minds is whether the vaccines being developed will be effective against this new variant. Despite apprehensions, there is some good news. Also Read - Akshay Kumar, Piyush Mishra, Sonam Kapoor and more Bollywood celebs who opened up on facing sexual abuse in childhood

Covaxin, India’s COVID-19 vaccine developed by Bharat Biotech for COVID-19, can offer effective protection against mutations of coronavirus, Chairman and Managing Director of the city-based vaccine maker Krishna Ella said on Tuesday. He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology and now undergoing phase 3 trials. Meanwhile government officials have gone on record to say that, so far, the mutations have not shown that they will have an impact on efficacy of vaccine. COVID-19 vaccines will work against new variants of the virus detected in the United Kingdom and South Africa, Prof K Vijay Raghavan, principal scientific advisor (PSA) to the Government of India, said on Tuesday. Also Read - Drinking Water On An Empty Stomach: 4 Health Benefits To Look Out For

Inactivated Vaccine effective against mutations

According to Ella, “COVID-19 is expected to have a lot of mutation and you can be rest assured this vaccine will also protect against that (mutated) virus because of two hypotheses. So, you have these two components in the inactivated vaccine. It will also take care of those mutations,” Ella said during a virtual programme organised by CSIR-Indian Institute of Chemical Technology. He was replying to a query on the new strain of coronavirus that was detected in the United Kingdom recently. Also Read - Test Article 2 Covid 19 3rd wave

Mutations are expected and can be dealt with

Ella said mutation was not unexpected and the virus mutates on its own to reach more people as it is a non-living organism. The executive said Covaxin, now undergoing Phase 3 trials involving about 20,000 volunteers, balances both safety and efficacy.

The new variant genome of SARS-CoV-2 was detected in 20 samples taken from UK returnees. All infected people are in isolation and their close contacts have also been put under quarantine. The presence of the new UK variant of the coronavirus has already been reported by Denmark, the Netherlands, Australia, Italy, Sweden, France, Spain, Switzerland, Germany, Canada, Japan, Lebanon and Singapore so far.

The vaccine scene in India

There are, at present, six COVID-19 vaccines in different clinical trial stages in India. Moreover, three vaccine candidates are also in pre-clinical trial stages. Pfizer, Serum Institute of India (SII) and Bharat Biotech have sought emergency use authorisation of their COVID-19 vaccines.

(With inputs from Agencies)

Published : December 30, 2020 9:14 am | Updated:December 31, 2020 8:06 am

AstraZeneca-Oxford COVID-19 vaccine not ready for approval in Europe: What about Covishield?

Genes linked to common brain disorder, Chiari 1 malformation, identified

About The health Site

Useful Links